摘要
目的:探讨氨磺必利治疗首发精神分裂症的临床疗效与安全性。方法:将60例首发精神分裂症患者,随机分为氨磺必利组30例,利培酮组30例,疗程8周。采用阳性与阴性症状量表(PANSS)评定疗效,采用治疗中出现的症状量表(TESS)评定不良反应。结果:氨磺必利组的治疗总有效率为86.6%,利培酮组的治疗总有效率为83.3%,两组疗效差异无统计学意义(P>0.05),氨磺必利组的体重增加明显少于利培酮组(P<0.05)。结论:两组疗效相当,氨磺必利引起体重增加明显减少。
Objective： To explore efficacy and safety of amisulpride in treatment of first-episode schizophrenia.Methods： 60 cases with first-episode schizophrenia were randomly divided into amisulpride group and risperidone group,and these cases were treated for 8 weeks.Positive and negative symptom scale（PANSS） and treatment emergent symptoms effect scale（TESS） were used to evaluate the efficacy and adverse effect,respectively.Results： After the treatment,the total effective rate of amisulpride group was 86.6% while that of risperidone group was 83.3%,and there was no significant difference between the two groups（P ＆gt; 0.05）.The weight gain of amisulpride group was significantly less than that of risperidone group（P ＆lt; 0.05）.Conclusions： Amisulpride and risperidone have a similar therapeutic effect,but the weight gain caused by amisulpride is significantly less.
出处
《中国民康医学》
2013年第15期30-31,共2页
Medical Journal of Chinese People’s Health
关键词
氨磺必利
利培酮
首发精神分裂症
Amisulpride
Risperidone
First-episode Schizophrenia
